Axonics Modulation Technologies, Inc.
https://www.axonics.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Axonics Modulation Technologies, Inc.
Bukwang Adds To Stacking Mid-Stage Failures In Parkinson's
Bukwang and subsidiary Contera have become the latest to fail to progress a novel Parkinson's therapy to late-stage trials after a Phase II miss, although several other Korean firms remain in the race for the challenging indication, albeit mainly in Phase I-II.
Updated: Boston Scientific Buys Axonics For $3.4BN; Adds Neuromodulation To Incontinence Lineup
Analysts support Boston Scientific's plan to buy Axonics for $3.4bn in cash. The deal is expensive, but gives Boston Scientific a strong position in the fast-growing sacral neuromodulation (SNM) therapy market and boosts its existing portfolio of products for incontinence.
Andera Bullish About Prospects For Europe's Biotechs
The France-based firm has assembled a strong syndicate for its sixth generation of 'BioDiscovery' funds, consolidating its position as one of the leading players in life sciences venture capital in Europe.
Medtronic Beats Back Axonics’ Challenge To InterStim Patents
The US patent office has upheld all seven patents at issue, with the verdict on the final three having come on 22 September.
Company Information
- Industry
-
Medical Devices
- Implantable Devices
-
Surgical Equipment & Devices
- Minimally or Less Invasive
- Other Names / Subsidiaries
-
- Contura Limited
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice